Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (ReWRAP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04002934|
Recruitment Status : Recruiting
First Posted : July 1, 2019
Last Update Posted : April 3, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS).
The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months.
Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigational new drug research study.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting||Drug: Bazedoxifene Acetate||Phase 2|
Multiple Sclerosis (MS) is a chronic neurologic disorder characterized by the loss of myelin, which results in disruption of nerve signal, damage to axons, and, ultimately, neurodegeneration. In order to treat MS, new methods for promoting repair (remyelination) are sorely needed.
There is a strong preclinical (including EAE) and epidemiologic rationale for investigating the remyelinating potential of estrogenic compounds, including evidence of endogenous (puberty, postpartum periods) and exogenous hormonal influences on MS risk and course. MS affects 3 times more women than men, and disease course in women appears overall less aggressive (on MRI, fewer T2-hyperintense demyelinated lesions develop into axonal destruction visualized as hypointense T1 "black holes").
Bazedoxifene (BZA), a third-generation SERM with extensive safety data in humans, was identified in a novel high-throughput screen (BIMA screen) for compounds capable of promoting remyelination. Subsequent analysis validated BZA's remyelinating effect in vitro and in vivo following demyelinating insult. Given strong pre-clinical support for BZA's remyelinating potential, and the clinical success of other compounds identified using the BIMA screen (Green et al., 2017), the investigators will investigate the use of BZA as a remyelinating therapy in patients with MS.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
This is a randomized, placebo controlled, double-blind, delayed-start trial of BZA in 50 women with MS to be given as follows:
Group A will receive 3 months of BZA + 3 months of BZA; Group B will receive 3 months of placebo + 3 months of BZA
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Delayed-Start Trial to Assess the Efficacy, Safety, and Tolerability of Bazedoxifene Acetate (BZA) as a Remyelinating Agent in Patients With Multiple Sclerosis|
|Actual Study Start Date :||September 10, 2019|
|Estimated Primary Completion Date :||February 15, 2024|
|Estimated Study Completion Date :||August 31, 2024|
Experimental: Group A
Group A is the "early-start" group and will receive a total of 6 months of BZA -- 3 months of BZA, followed by 3 months BZA
Drug: Bazedoxifene Acetate
40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
Experimental: Group B
Group B is the "delayed-start" group and will receive a total of 3 months of BZA -- 3 months of placebo, followed by 3 months of BZA
Drug: Bazedoxifene Acetate
40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
- P100 Latency on Full Field Visual Evoked Potential [ Time Frame: 3 months ]The primary objective is to evaluate the efficacy of BZA relative to placebo for reducing P100 latencies on full field transient pattern reversal visual evoked potentials (VEPs). In response to a visual stimulus, cortically generated electrical potentials (VEPs) recorded over the scalp are used to measure the functional integrity of visual pathways.
- P100 Latency on Full Field Visual Evoked Potential [ Time Frame: 6 months ]Assess whether P100 latency delay at 6 months decreases to a greater extent in Group A (exposed to BZA for 3 months during both Stage 1 and Stage 2 -- 6 months total) when compared to Group B (exposed to placebo during Stage 1 and BZA for 3 months during Stage 2 -- 3 months total).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||40 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Women aged 45-65 or 40+ post-menopausal.
- Documentation of a clinically definite diagnosis of relapsing-remitting MS
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
- Latency delay > 118 milliseconds on baseline full-field transient pattern reversal VEP in at least one eye (electrophysiological evidence of demyelination)
- RNFL > 70 microns on SD-OCT in the same eye meeting criteria for latency delay (sufficient axons)
- Stable immunomodulatory therapy - no switch or planned switch in > 6 months and no change in doses in 30 days prior to screening
- Use of contraceptive method with ≤1% failure rate during period of trial if premenopausal
- Understand and sign informed consent.
- EDSS 0-6.0 (inclusive)
- Multiple Sclerosis disease duration > 25 years
- Optic neuritis in prior 6 months
- Known optic neuritis in involved eye ≥ 10 years ago
- Major ophthalmologic disease/Concomitant ophthalmologic disorders (e.g. diabetes, macular degeneration, glaucoma, severe myopia, etc.).
- Myopia > -7 Diopters (severe myopia)
- Disc hemorrhages in qualifying eye
- No light perception in qualifying eye
- Simultaneous bilateral optic neuritis
- Cotton wool spots in qualifying eye
- Macular star in qualifying eye
- History of significant cardiac conduction block
- History of cancer (except non-melanoma skin cancer)
- Suicidal ideation or behavior in 6 months prior to baseline
- Pregnancy, breastfeeding, or planning to become pregnant
- Included with other study protocol simultaneously without prior approval
- Concomitant or prior use of any other putative remyelinating therapy as determined by investigator, including but not limited to Clemastine, Duavee, and Tamoxifen.
- Serum creatinine > 1.5mg/dL; AST, ALT, or alkaline phosphatase > 2 times the upper limit of normal
- History of drug or alcohol abuse within the past year
- Untreated B12 deficiency (as determined by B12 serological assessments and metabolites including methylmalonic acid [MMA] and homocysteine) or untreated hypothyroidism
- Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal or other major diseases that in the PI's judgement may affect interpretation of study results or patient safety.
- History of or presence of clinically significant medical illness or laboratory abnormality that, in the opinion of the investigator would preclude participation in the study.
- Patients whose lack of mobility exposes them to an increased risk of venous thromboembolism
- Patients with undiagnosed uterine bleeding
- Patients with unknown, suspected or past history of breast cancer
- Patients with known or suspected estrogen-dependent neoplasia
- Patients with active or a past history of venous thromboembolism
- Patients with active or a past history of arterial thromboembolism
- Patients with known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders
- Patients with hypersensitivity (angioedema, anaphylaxis) to estrogens, bazedoxifene, or any ingredients
- Patients with known hepatic impairment or disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04002934
|Contact: Annika Andersonfirstname.lastname@example.org|
|Contact: William Rowlesemail@example.com|
|United States, California|
|Weill Institute for Neurosciences, University of California, San Francisco||Recruiting|
|San Francisco, California, United States, 94158|
|Contact: Annika Anderson 415-353-8903 firstname.lastname@example.org|
|Contact: William Rowles 415-502-7209 email@example.com|
|Principal Investigator: Riley Bove, MD|
|Principal Investigator:||Riley M Bove, MD MMSc||University of California, San Francisco|
|Responsible Party:||Riley Bove, MD, Assistant Professor of Neurology, University of California, San Francisco|
|Other Study ID Numbers:||
138495 ( Other Identifier: FDA -- Investigational New Drug Number )
18-24511 ( Other Identifier: UCSF IRB No. )
|First Posted:||July 1, 2019 Key Record Dates|
|Last Update Posted:||April 3, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Immune System Diseases
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Bone Density Conservation Agents